PI4K Inhibitor

PI4K Inhibitors (21):

Cat. No.	Product Name	Effect	Purity

HY-12046

PIK-93	Inhibitor	99.81%
PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC₅₀ of 19 nM, and also inhibits PI3Kγ and PI3Kα with IC₅₀ of 16 nM and 39 nM, respectively.

HY-100198

PI4KIIIbeta-IN-10	Inhibitor	99.84%
PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC₅₀ of 3.6 nM.

HY-103489

PI-273	Inhibitor	≥98.0%
PI-273 is a first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC₅₀ of 0.47 μM. PI-273 can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.

HY-U00426

BF738735	Inhibitor	99.10%
BF738735 is a phosphatidylinositol 4-kinase III beta (PI4KIIIβ) inhibitor with an IC₅₀ of 5.7 nM.

HY-108313

T-00127_HEV1	Inhibitor	99.97%
T-00127_HEV1 is a phosphatidylinositol 4-kinase III beta (PI4KB) inhibitor with an IC₅₀ of 60 nM.

HY-118525

AL-9	Inhibitor
AL-9 is a inhibitor of PI4KIIIα, with the IC₅₀ of 0.57 μM, that can inhibit HCV replication.

HY-125118

GSK-A1	Inhibitor	≥99.0%
GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC₅₀ of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC₅₀ of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research.

HY-19798

PI4KIIIbeta-IN-9	Inhibitor	99.01%
PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC₅₀ of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC₅₀s of 152 nM and 1046 nM, respectively.

HY-12912

KDU691	Inhibitor	99.42%
KDU691, an imidazopyrazine with potent anti-parasitic activity against blood stage schizonts, gametocytes and liver stages, is a Plasmodium PI4K inhibitor. KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites.

HY-15679

PI4KIII beta inhibitor 3	Inhibitor	99.77%
PI4KIII beta inhibitor 3 is a novel and high effective PI4KIIIβ inhibitor with IC₅₀ of 5.7 nM.

HY-18748

BQR-695	Inhibitor	99.92%
BQR-695 is a PI4KIIIβ inhibitor with IC₅₀s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.

HY-106005

MMV390048	Inhibitor	99.17%
MMV390048 is a representative of a new chemical class of Plasmodium PI4K inhibitor (K_d^app=0.3 µM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns. MMV390048 is an antimalarial agent.

HY-112613

UCB9608	Inhibitor	99.43%
UCB9608 is a potent, selective and orally active PI4KIIIβ inhibitor, with an IC₅₀ of 11 nM, selective over PI3KC2 α, β, and γ lipid kinases. UCB9608 improves metabolic stability and exhibits excellent pharmacokinetic profile, acts as a potent immunosuppressive agent.

HY-150023

BI-1622	Inhibitor	98.97%
BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC₅₀ of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile.

HY-106012

PI4K-IN-1	Inhibitor
PI4K-IN-1 (compound 44) is a potent PI4KIII inhibitor, with pIC₅₀ values of 9.0 and 6.6 for PI4KIIIα and PI4KIIIβ, respectively. PI4K-IN-1 also inhibits PI3Kα/β/γ/δ, with pIC₅₀ values of 4.0/<3.7/5.0/<4.1, respectively.

HY-103583

KDU731	Inhibitor	98.0%
KDU731, an orally active C. parvum PI4K inhibitor with an IC₅₀ value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo. KDU731 is a promising agent candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety.

HY-112435

UCT943	Inhibitor	98.70%
UCT943 is a next-generation Plasmodium falciparum PI4K inhibitor. UCT943 inhibits the P. vivax PI4K (PvPI4K) enzyme with an IC₅₀ of 23 nM.

HY-156685

EDI048	Inhibitor
EDI048 (compound 1.16) is an orally active Cryptosporidium PI4K inhibitor for the research of cryptosporidiosis.

HY-148075

PI4KIIIbeta-IN-11	Inhibitor
PI4KIIIbeta-IN-11 is an inhibitor of PI4KIIIβ, with a mean pIC₅₀ value of at least 9.1. PI4KIIIβ plays a key role in diseases research of RNA viruses and Plasmodium falciparum.

HY-150598

CHMFL-PI4K-127	Inhibitor
CHMFL-PI4K-127 (compound 15g) is an orally active, potent and high selective PfPI4K (Plasmodium falciparum PI4K kinase) inhibitor, with an IC₅₀ of 0.9 nM. CHMFL-PI4K-127 exhibits potent activity against 3D7 Plasmodium falciparum, with an EC₅₀ of 25.1 nM. CHMFL-PI4K-127 shows antimalaria efficacy.

Name
Email *

	Sorry, but the email address you supplied was invalid.